TRCT
IHE icon

Tower Research Capital (TRC)’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Tower Research Capital (TRC)’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,159
Closed -$592K – 5356
2025
Q3 		$592K Sell
8,159
-9,957
-55% -$687K 0.02% 756
2025
Q2 		$1.19M Buy
18,116
+3,728
+26% +$243K 0.03% 475
2025
Q1 		$1.02M Buy
+14,388
New +$1,000K 0.03% 492
2024
Q4 		– Sell
-4,012
Closed -$283K – 5829
2024
Q3 		$283K Buy
4,012
+3,207
+398% +$223K 0.01% 1304
2024
Q2 		$53.4K Sell
805
-5,613
-87% -$368K ﹤0.01% 3055
2024
Q1 		$436K Sell
6,418
-123,653
-95% -$8.17M 0.01% 942
2023
Q4 		$8.04M Buy
130,071
+124,440
+2,210% +$7.31M 0.1% 161
2023
Q3 		$332K Sell
5,631
-180
-3% -$11K 0.01% 1119
2023
Q2 		$347K Sell
5,811
-354
-6% -$21K 0.01% 1214
2023
Q1 		$360K Buy
6,165
+4,401
+249% +$265K 0.01% 1026
2022
Q4 		$109K Sell
1,764
-10,725
-86% -$645K ﹤0.01% 1766
2022
Q3 		$706K Sell
12,489
-35,805
-74% -$2.21M 0.01% 889
2022
Q2 		$3.08M Buy
48,294
+42,600
+748% +$2.7M 0.07% 234
2022
Q1 		$369K Buy
+5,694
New +$361K ﹤0.01% 1333
2021
Q4 		– Sell
-2,055
Closed -$125K – 6335
2021
Q3 		$125K Buy
+2,055
New +$131K ﹤0.01% 2206
2021
Q2 		– Sell
-7,191
Closed -$426K – 5639
2021
Q1 		$426K Sell
7,191
-104,745
-94% -$6.32M 0.01% 1372
2020
Q4 		$6.7M Buy
111,936
+104,082
+1,325% +$5.93M 0.2% 46
2020
Q3 		$428K Sell
7,854
-17,667
-69% -$953K ﹤0.01% 1855
2020
Q2 		$1.31M Buy
+25,521
New +$1.28M 0.05% 375
2019
Q4 		– Sell
-1,134
Closed -$53K – 3903
2019
Q3 		$53K Sell
1,134
-21,072
-95% -$1.01M ﹤0.01% 1759
2019
Q2 		$1.12M Sell
22,206
-7,698
-26% -$381K 0.08% 236
2019
Q1 		$1.53M Buy
+29,904
New +$1.49M 0.09% 169
2018
Q4 		– Sell
-8,904
Closed -$498K – 4056
2018
Q3 		$498K Sell
8,904
-1,431
-14% -$78.2K 0.04% 477
2018
Q2 		$521K Buy
+10,335
New +$512K 0.03% 627
2016
Q1 		– Sell
-91,428
Closed -$4.93M – 4497
2015
Q4 		$4.93M Sell
91,428
-6,645
-7% -$350K 0.8% 12
2015
Q3 		$4.84M Buy
98,073
+72,609
+285% +$4.16M 0.47% 22
2015
Q2 		$1.48M Buy
25,464
+10,545
+71% +$616K 0.13% 69
2015
Q1 		$857K Sell
14,919
-6,906
-32% -$378K 0.11% 121
2014
Q4 		$1.1M Sell
21,825
-53,325
-71% -$2.6M 0.11% 90
2014
Q3 		$3.52M Buy
75,150
+49,737
+196% +$2.24M 0.39% 44
2014
Q2 		$1.14M Sell
25,413
-87,489
-77% -$3.76M 0.15% 78
2014
Q1 		$4.77M Buy
112,902
+100,050
+778% +$4.19M 0.61% 26
2013
Q4 		$506K Buy
+12,852
New +$482K 0.08% 180

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s IHE Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2025, closing a stake of 8,159 shares — an estimated $592K sold.

Tower Research Capital (TRC) first reported a position in IHE in Q4 2013 and held it in 33 quarters. The position peaked at $8.04M in Q4 2023. 178 funds tracked by Wall St. Rank hold IHE as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,159 iShares US Pharmaceuticals ETF shares in Q4 2025, an estimated $592K.
  • Tower Research Capital (TRC) first reported a position in iShares US Pharmaceuticals ETF in Q4 2013 and held it in 33 quarters.
  • Tower Research Capital (TRC)'s iShares US Pharmaceuticals ETF position peaked at $8.04M in Q4 2023.
  • 178 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.